• Vol. 48 No. 3, 98–103
  • 15 March 2019

Empiric Meropenem-based versus Ceftazidime-based Therapy for Severe Community-Acquired Pneumonia in a Retrospective Cohort Study

490






490 Views
128 Downloads

Download PDF

Optimal antibiotic regimen is unknown for severe community-acquired pneumonia (SCAP) which has mortality rates of up to 67% locally.1 Recommended empiric regimens from the West cannot be extrapolated to our region where melioidosis is endemic2 and Streptococcus pneumoniae penicillin resistance is common.3 Unfortunately, studies that compare optimal antibiotic regimens for SCAP in Southeast Asia are lacking.

This article is available only as a PDF. Please click on “Download PDF” on top to view the full article.